Elevance Health (NYSE: ELV) CFO receives stock awards and withholds shares for taxes

Rhea-AI Filing Summary

Elevance Health EVP & CFO Mark Kaye reported multiple equity compensation transactions. He received grants of 6,377 and 10,202 restricted stock units, with restrictions scheduled to lapse between March 2, 2027 and March 2, 2029, and a stock option covering 25,188 shares exercisable in three annual installments beginning on March 2, 2027.

To cover tax liabilities tied to previously granted restricted stock vesting, he disposed of 353 and 271 common shares at prices of $284.03 and $294.07 per share through share withholding, rather than open-market sales.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Kaye Mark

Role EVP & CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	353	$284.03	$100K
Grant/Award	Employee Stock Option (Right to Buy)	25,188	$0.00	--
Tax Withholding	Common Stock	271	$294.07	$80K
Grant/Award	Common Stock	6,377	$0.00	--
Grant/Award	Common Stock	10,202	$0.00	--

Holdings After Transaction: Common Stock — 32,037 shares (Direct); Employee Stock Option (Right to Buy) — 25,188 shares (Direct)

Footnotes (1)

1. PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Represents restricted share units. Restrictions lapse as follows: 2,125 shares on 3/2/2027, and 2,126 shares each on 3/2/2028 and 3/2/2029. Represents restricted share units. Restrictions lapse as follows: 5,101 shares each on 3/2/2027 and 3/2/2028. The option represents a right to purchase a total of 25,188 shares, and is exercisable in three annual installments, each installment of 8,396 shares, beginning on 3/2/2027, which is the one-year anniversary of the option grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Mark

(Last) (First) (Middle)

220 VIRGINIA AVENUE

(Street)

INDIANAPOLIS IN 46204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elevance Health, Inc. [ ELV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F		271(1)	D	$294.07	15,811	D
Common Stock	03/02/2026		A		6,377(2)	A	$0	22,188	D
Common Stock	03/02/2026		A		10,202(3)	A	$0	32,390	D
Common Stock	03/03/2026		F		353(1)	D	$284.03	32,037	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$294.07	03/02/2026		A		25,188		(4)	03/02/2036	Common Stock	25,188	$0	25,188	D

Explanation of Responses:

1. PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

2. Represents restricted share units. Restrictions lapse as follows: 2,125 shares on 3/2/2027, and 2,126 shares each on 3/2/2028 and 3/2/2029.

3. Represents restricted share units. Restrictions lapse as follows: 5,101 shares each on 3/2/2027 and 3/2/2028.

4. The option represents a right to purchase a total of 25,188 shares, and is exercisable in three annual installments, each installment of 8,396 shares, beginning on 3/2/2027, which is the one-year anniversary of the option grant date.

Remarks:

	/s/ Kathleen S. Kiefer, Attorney in fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elevance Health EVP & CFO Mark Kaye report in this Form 4 for ELV?

Mark Kaye reported routine equity compensation activity, including new restricted stock units, a stock option grant, and share withholdings for taxes. The transactions reflect awards and tax-settlement mechanics rather than open-market buying or selling of Elevance Health common stock.

How many restricted stock units did Mark Kaye receive from Elevance Health (ELV)?

Mark Kaye received grants of 6,377 and 10,202 restricted stock units in separate awards. The restrictions are scheduled to lapse in tranches between March 2, 2027 and March 2, 2029, aligning vesting with multi-year service and performance periods at Elevance Health.

What are the terms of Mark Kaye’s new stock option award at Elevance Health (ELV)?

The new option gives Mark Kaye the right to purchase 25,188 ELV shares. It vests in three equal annual installments of 8,396 shares, beginning on March 2, 2027, the one-year anniversary of the grant date, creating a staggered long-term incentive structure.

Were Mark Kaye’s Form 4 share disposals in ELV open-market sales?

No, the disposals were share withholdings to satisfy tax liabilities on vesting restricted stock. Elevance Health withheld 353 and 271 common shares at set prices, classified under code “F,” rather than selling shares through open-market transactions initiated by Mark Kaye.

At what prices were shares withheld for Mark Kaye’s tax obligations at Elevance Health (ELV)?

Shares were withheld at prices of $284.03 and $294.07 per share. These withholdings, totaling 353 and 271 shares respectively, were used to cover tax liabilities associated with previously granted restricted stock as those awards vested for Mark Kaye.

When do Mark Kaye’s Elevance Health restricted stock units vest?

One RSU award vests 2,125 shares on March 2, 2027, then 2,126 shares on March 2, 2028 and 2029. Another vests 5,101 shares on March 2, 2027 and 5,101 on March 2, 2028, creating staged multi-year vesting.